LIPG and breast carcinoma: To reveal whether XEN445 inhibits cell viability in a LIPG-dependent manner, we treated two LIPG-expressing TNBC cell lines (MCF10DCIS and MDA-MB-468) and two LIPG-deficient luminal breast cancer (LuBC) cell lines (MCF7 and T47D)16 with XEN445 at two different doses (200 and 250 μM).